CMS subsidiary Dermavon gets China approval for additional Lumirix indication
CMS says its subsidiary Dermavon has received approval in China for an additional indication of Lumirix(R) for atopic dermatitis (AD).
SHENZHEN, CHINA, Sept 4, 2026 - (ACN Newswire) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing o…